Brief: Alzamend Neuro Announces Full Data Set From Its Nonclinical Study

Alzamend Neuro

19/11/2024 13:23

Nov 19 (Reuters) - Alzamend Neuro Inc  ALZN.O :
    * ALZAMEND NEURO ANNOUNCES FULL DATA SET FROM ITS
NONCLINICAL
STUDY: COMPARING BRAIN AND PLASMA LITHIUM EXPOSURES BETWEEN
AL001 AND LITHIUM CARBONATE IN ALZHEIMER’S TRANSGENIC MICE
    * ALZAMEND NEURO INC: AT A LOW DOSE, AL001 EVIDENCED
CONSISTENTLY
HIGHER LITHIUM CONCENTRATIONS THAN LITHIUM CARBONATE WITHIN
CRITICAL BRAIN REGIONS
    * ALZAMEND NEURO INC: BOTH TREATMENTS HAD NO NEGATIVE IMPACT
ON
MICE'S BODY WEIGHT OR CLINICAL SIGNS DURING TREATMENT PERIOD
    * ALZAMEND NEURO INC: AL001 SHOWED LOWER PLASMA LITHIUM
LEVELS
THAN LITHIUM CARBONATE, REDUCING RISK OF ADVERSE SYSTEMIC
EFFECTS

Source text:  ID:nBw9l32QHa 
Further company coverage:  ALZN.O 

 ((Reuters.Briefs@thomsonreuters.com;))